Syros Pharmaceuticals Inc (NASDAQ:SYRS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.

According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

A number of other equities analysts have also issued reports on SYRS. Piper Jaffray Cos. began coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “overweight” rating and a $20.00 target price on the stock. Wedbush began coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “outperform” rating and a $18.00 target price on the stock. HC Wainwright reaffirmed a “hold” rating and set a $10.00 target price on shares of Syros Pharmaceuticals in a research report on Friday, September 9th. JMP Securities began coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They set an “outperform” rating and a $22.00 target price on the stock. Finally, Cowen and Company began coverage on shares of Syros Pharmaceuticals in a report on Monday, July 25th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $17.50.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/syros-pharmaceuticals-inc-syrs-cut-to-sell-at-zacks-investment-research.html

Syros Pharmaceuticals (NASDAQ:SYRS) opened at 13.25 on Thursday. The firm’s market cap is $309.71 million. The firm’s 50-day moving average is $11.67 and its 200 day moving average is $12.69. Syros Pharmaceuticals has a 1-year low of $8.16 and a 1-year high of $21.50.

In other Syros Pharmaceuticals news, Director Robert Nelsen purchased 400,000 shares of the stock in a transaction on Wednesday, July 6th. The shares were purchased at an average price of $12.50 per share, with a total value of $5,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Redmile Group, Llc purchased 432,746 shares of the stock in a transaction on Wednesday, July 6th. The stock was acquired at an average cost of $12.50 per share, for a total transaction of $5,409,325.00. The disclosure for this purchase can be found here.

A number of large investors have recently made changes to their positions in SYRS. Weiss Multi Strategy Advisers LLC acquired a new stake in shares of Syros Pharmaceuticals during the second quarter valued at about $832,000. Aisling Capital LLC purchased a new stake in shares of Syros Pharmaceuticals during the second quarter valued at approximately $16,490,000. Redmile Group LLC purchased a new stake in shares of Syros Pharmaceuticals during the second quarter valued at approximately $15,058,000. Deerfield Management Co. purchased a new stake in shares of Syros Pharmaceuticals during the second quarter valued at approximately $38,028,000. Finally, Flagship Ventures Fund IV General Partner LLC purchased a new stake in shares of Syros Pharmaceuticals during the second quarter valued at approximately $87,241,000.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

5 Day Chart for NASDAQ:SYRS

Receive News & Ratings for Syros Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.